Matinas BioPharma Reports $1.92 Million Net Loss in Q1 2026, Focuses on Partnerships

Matinas BioPharma Holdings, Inc. reported a net loss of $1.92 million for the first quarter of 2026, compared to a net loss of $1.66 million during the same period in 2025. The company’s total operating expenses for the quarter were $1.94 million, slightly down from $1.95 million in the previous year. The decrease in expenses was primarily due to a significant reduction in research and development costs, which fell to zero from $85,000 in the prior year, as the company paused its development program for MAT2203. General and administrative expenses increased to $1.94 million from $1.86 million, attributed to higher legal and consulting fees.

As of March 31, 2026, Matinas BioPharma's total assets were reported at $5.87 million, a decrease from $7.21 million at the end of 2025. The decline in assets was primarily driven by a reduction in cash and cash equivalents, which fell to $2.40 million from $4.00 million. The company’s current liabilities increased to $2.13 million from $1.46 million, largely due to higher accounts payable and accrued expenses. Stockholders' equity also decreased significantly to $3.02 million from $4.83 million, reflecting the ongoing losses and operational challenges faced by the company.

In terms of strategic developments, Matinas BioPharma is focusing on securing partnerships to monetize its lead product candidate, MAT2203, and is exploring options for additional funding. The company has not engaged in any sales under its At-The-Market Sales Agreement during the first quarter of 2026, leaving an available capacity of approximately $44.19 million. The company’s management has indicated that it will continue to seek collaborations, licensing arrangements, and other financing options to support its operations and product development.

Operationally, Matinas BioPharma has not reported any significant changes in customer counts or user statistics, as the focus remains on advancing its clinical-stage product candidates. The company has maintained its employee headcount at approximately 6,406, consistent with the previous year. The management anticipates that research and development expenses will remain lower in the near term until additional funding is secured to support further clinical studies.

Looking ahead, Matinas BioPharma acknowledges substantial doubt about its ability to continue as a going concern, given its current cash position and ongoing losses. The company plans to conserve cash while exploring strategic options, including potential partnerships for MAT2203. However, the management cautions that without successful fundraising or strategic transactions, the company may face significant operational challenges in the future.